The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer-goods editor and analyst Austin Smith discuss topics around the investing world.

In this video, David and Austin discuss the recent news surrounding obesity-drug makers. With an overwhelmingly favorable FDA advisory panel recommending approval for Qnexa by a 20-2 vote, what does that mean for its maker, VIVUS, and for its competitors Arena Pharmaceuticals and Orexigen? Is Qnexa poised to reap all of the rewards?